A sum of $500 might not seem like much of an investment, but if you select the right pharmaceutical stocks -- and are patient enough to hold them forever -- history shows you'll have a very high chance of ending up with many times more money than at the start. With that in mind, let's examine three leading ...
motleyfoolusx:vrtx
Vertex Pharmaceuticals (NASDAQ: VRTX) is a fast-growing pharmaceutical company that investors have been bullish on for years. The business generates billions in revenue from cystic fibrosis drugs, and it has been working on diversifying its portfolio to include a wider array of products. Today, the stock ...
motleyfoolusx:vrtx
The stock market has performed relatively well since the beginning of the year although, of course, there is no guarantee that it will maintain that momentum. Who knows what curve ball the future has in store for us? Regardless of what happens, investing in market leaders with robust underlying businesses ...
motleyfoolusx:regnusx:vrtx
What's better than a stock that has delivered huge gains? That's easy: A stock that has delivered huge gains and still has a lot of room to run. We asked three Motley Fool contributors to look among recently high-flying stocks for those that they believe could soar by significantly more. Here's why they ...
motleyfoolusx:llyusx:vrtxusx:nvo
There are several textbook arguments against monopolies. According to one of them, companies that control a market can lower the quality of their products with impunity. However, Vertex Pharmaceuticals (NASDAQ: VRTX), a drugmaker with a monopoly in the cystic fibrosis (CF) market, hasn't done that -- ...
motleyfoolusx:vrtx
The stock market has taken investors for a wild ride these last few years. When you're investing in stocks for many years, though, even multiple tough market cycles shouldn't deter you from your core investing thesis about quality companies. Even as the S&P 500 has had a pretty fantastic 2024 so far, ...
motleyfoolusx:vrtx
While some stocks have responded to the 2024 bull market better than others, an abundance of stocks have followed this rising tide. There's no predicting how long this next bull market will last, although historically speaking, these periods tend to significantly outlast bear markets in average duration. ...
motleyfoolusx:vrtx
As investing legends like Warren Buffett probably know better than anyone, there's something satisfying about buying shares of a company you intend to hold for the rest of your career as an investor. By making a commitment to remaining patient for the long haul as the money trickles in, you're also demonstrating ...
motleyfoolusx:vrtx
No risk, no reward. That's a fundamental part of investing. However, some stocks are less risky than others and still offer strong growth prospects. Three Motley Fool contributors think they've found relatively safe growth stocks you can buy and hold. Here's why they picked Eli Lilly (NYSE: LLY), Novo ...
motleyfoolusx:llyusx:vrtxusx:nvo
Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) continues to grab headlines. Over the past six months, the drugmaker has earned important regulatory approvals and made excellent clinical progress. But the company isn't stopping. Vertex just announced a move that will help it expand its pipeline. ...
motleyfoolusx:vrtxusx:alpn
Biotech acquisitions continue to abound this year. On April 10, Vertex Pharmaceuticals (NASDAQ: VRTX) announced it would purchase Alpine Immune Sciences (NASDAQ: ALPN) for $4.9 billion in cash in a deal that's set to close before the end of this quarter. The prized asset that Vertex will gain as part ...
motleyfoolusx:vrtxusx:alpn
Vertex Pharmaceuticals (NASDAQ: VRTX) has a promising healthcare business with many growth opportunities ahead. But with the stock such a hot buy over the past few years and its valuation now hitting the $100 billion mark, has it become too expensive of an investment? Is it time for investors to consider ...
motleyfoolusx:vrtx
